"AI-based Drug Discovery for Targeted Radioligand Therapy"

Our research group is dedicated to developing therapeutic and diagnostic peptides using a cutting-edge, AI-driven approach. By integrating state-of-the-art technologies—including diffusion models, predictive AI, and protein language models—alongside rigorous evaluation of biochemical and physical properties, we aim to design and screen peptide candidates with increased efficiency and precision. Our research targets key cancer biomarkers, specifically focusing on pancreatic, lung, and breast cancers. Ultimately, our goal is to develop peptides for use in radioligand therapy, thereby enhancing the precision and effectiveness of treatment across selected cancer targets. Through this work, we aspire to set new standards in peptide-based cancer diagnostics and therapeutics.